Novo Nordisk A/S (NYSE:NVO) Shares Bought by Apeiron RIA LLC

Apeiron RIA LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 25.3% during the fourth quarter, Holdings Channel reports. The firm owned 5,935 shares of the company’s stock after buying an additional 1,199 shares during the period. Apeiron RIA LLC’s holdings in Novo Nordisk A/S were worth $510,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Strategic Investment Solutions Inc. IL bought a new stake in Novo Nordisk A/S in the second quarter valued at $25,000. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth about $28,000. Capital Performance Advisors LLP bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $42,000. Albion Financial Group UT boosted its stake in Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares during the period. Finally, Carolina Wealth Advisors LLC bought a new position in Novo Nordisk A/S in the 3rd quarter worth about $48,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 1.0 %

Shares of Novo Nordisk A/S stock opened at $81.36 on Friday. The business has a fifty day simple moving average of $96.10 and a 200-day simple moving average of $115.79. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The firm has a market cap of $365.09 billion, a price-to-earnings ratio of 26.33, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on NVO. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets reduced their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.